Basoglu, T.; Ozkerim, U.; Oksuz, S.; Kinikoglu, O.; Yildirim, S.; Kokten, S.; Surmeli, H.; Isik, D.; Sever, O.N.; Ay Ersoy, S.;
et al. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage. J. Clin. Med. 2025, 14, 7103.
https://doi.org/10.3390/jcm14197103
AMA Style
Basoglu T, Ozkerim U, Oksuz S, Kinikoglu O, Yildirim S, Kokten S, Surmeli H, Isik D, Sever ON, Ay Ersoy S,
et al. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage. Journal of Clinical Medicine. 2025; 14(19):7103.
https://doi.org/10.3390/jcm14197103
Chicago/Turabian Style
Basoglu, Tugba, Ugur Ozkerim, Sila Oksuz, Oguzcan Kinikoglu, Sedat Yildirim, Sermin Kokten, Heves Surmeli, Deniz Isik, Ozlem Nuray Sever, Seval Ay Ersoy,
and et al. 2025. "Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage" Journal of Clinical Medicine 14, no. 19: 7103.
https://doi.org/10.3390/jcm14197103
APA Style
Basoglu, T., Ozkerim, U., Oksuz, S., Kinikoglu, O., Yildirim, S., Kokten, S., Surmeli, H., Isik, D., Sever, O. N., Ay Ersoy, S., Odabas, H., & Turan, N.
(2025). Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage. Journal of Clinical Medicine, 14(19), 7103.
https://doi.org/10.3390/jcm14197103
